Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy

Urine proteome analysis is rapidly emerging as a tool for diagnosis and prognosis in disease states. For diagnosis of diabetic nephropathy (DN), urinary proteome analysis was successfully applied in a pilot study. The validity of the previously established proteomic biomarkers with respect to the di...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2010-10, Vol.5 (10), p.e13421-e13421
Main Authors: Alkhalaf, Alaa, Zürbig, Petra, Bakker, Stephan J L, Bilo, Henk J G, Cerna, Marie, Fischer, Christine, Fuchs, Sebastian, Janssen, Bart, Medek, Karel, Mischak, Harald, Roob, Johannes M, Rossing, Kasper, Rossing, Peter, Rychlík, Ivan, Sourij, Harald, Tiran, Beate, Winklhofer-Roob, Brigitte M, Navis, Gerjan J
Format: Article
Language:English
Subjects:
Biological markers
Biomarkers
Biomarkers - urine
Biotechnology/Protein Chemistry and Proteomics
Capillary electrophoresis
Cardiovascular disease
Case-Control Studies
Collagen (type I)
Coronary vessels
Diabetes
Diabetes and Endocrinology/Type 2 Diabetes
Diabetes mellitus
Diabetes therapy
Diabetic nephropathies
Diabetic Nephropathies - urine
Diabetic nephropathy
Diabetic retinopathy
Diabetics
Diagnosis
Diagnostic systems
Disease prevention
Electrophoresis, Capillary
Ethics
Humans
Identification
Internal medicine
Kidney diseases
Kidneys
Laboratories
Limit of Detection
Mass Spectrometry
Mass spectroscopy
Medical research
Medicine
Metabolism
Nephrology/Chronic Kidney Disease
Nephropathy
Patients
Peptides
Proteomics
Retinopathy
Scientific imaging
Type 2 diabetes
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Urine proteome analysis is rapidly emerging as a tool for diagnosis and prognosis in disease states. For diagnosis of diabetic nephropathy (DN), urinary proteome analysis was successfully applied in a pilot study. The validity of the previously established proteomic biomarkers with respect to the diagnostic and prognostic potential was assessed on a separate set of patients recruited at three different European centers. In this case-control study of 148 Caucasian patients with diabetes mellitus type 2 and duration ≥5 years, cases of DN were defined as albuminuria >300 mg/d and diabetic retinopathy (n = 66). Controls were matched for gender and diabetes duration (n = 82). Proteome analysis was performed blinded using high-resolution capillary electrophoresis coupled with mass spectrometry (CE-MS). Data were evaluated employing the previously developed model for DN. Upon unblinding, the model for DN showed 93.8% sensitivity and 91.4% specificity, with an AUC of 0.948 (95% CI 0.898-0.978). Of 65 previously identified peptides, 60 were significantly different between cases and controls of this study. In
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0013421